Evidence map›Paper›PMID 30477095›Full record

ReviewHealthcare (Basel, Switzerland)2018

Sclerostin Modulation Holds Promise for Dental Indications.

Mohamed G Hassan, Abbas R Zaher, Juan Martin Palomo, Leena Palomo

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamed G HassanDivision of Craniofacial Anomalies, Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, USA. mgamal@dent.svu.edu.eg.
Abbas R ZaherDepartment of Orthodontics, Faculty of Dentistry, Alexandria University, Alexandria 21526, Egypt. azaher@drabbaszaher.com.
Juan Martin PalomoDepartment of Orthodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA. palomo@case.edu.
Leena PalomoDepartment of Periodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA. leena.palomo@case.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.

Indexed as

alveolar boneanti-sclerostinbone lossbone remodelingorthodonticperiodontitissclerostintooth movement

Identifiers

PMID30477095
PMCPMC6316148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.